Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Baseline clinical characteristics of study eyes.

From: Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study

Characteristic Study eye
Best-corrected VA (logMAR)  
   N 73
   Mean (SD) 0.62 (0.24)
   Median (range) 0.54 (-0.18 -- 1.00)
Time from NV-AMD diagnosis to baseline, months  
   N 73
   Mean (SD) 2.4 (5.9)
   Median (range) 0 (0 -- 31)
Angiographic subtype, n (%)  
   Minimally classic 4 (5.5)
   Occult 55 (75.3)
   Predominantly classic 11 (15.1)
   Missing 3 (4.1)
Lesion size (disc area), n (%)  
   < 2 26 (35.6)
   ≥ 2 and < 4 22 (30.1)
   ≥ 4 11 (15.1)
   Missing 14 (19.2)
Lesion location, n (%)  
   Subfoveal 60 (82.2)
   Extrafoveal 1 (1.4)
   Juxtafoveal 6 (8.2)
   Missing 6 (8.2)
Pigment epithelial detachment, n (%)  
   Absent 46 (63.0)
   Present 16 (21.9)
   Missing 11 (15.1)
Retinal angiomatous proliferation, n (%)  
   Absent 58 (79.5)
   Present 1 (1.4)
   Missing 14 (19.2)
Cystoid macular oedema, n (%)  
   Absent 52 (71.2)
   Present 7 (9.6)
   Missing 14 (19.2)
Fibrosis, n (%)  
   Absent 57 (78.1)
   Present 3 (4.1)
   Missing 13 (17.8)
Geographic atrophy, n (%)  
   Absent 54 (74.0)
   Present 10 (13.7)
   Missing 9 (12.3)
Presence of blood, n (%)  
   Yes 25 (34.2)
   No 43 (58.9)
   Missing 5 (6.8)
Estimated percentage of lesion with blood, n (%)  
   ≤ 50% 12 (16.4)
   > 50% 3 (4.1)
   Missing 58 (79.5)
  1. NV-AMD = neovascular age-related macular degeneration; SD = standard deviation; VA = visual acuity.